Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Interferon alfa-2b
Drug ID BADD_D01167
Description Interferon alpha 2b (human leukocyte clone hif-sn 206 protein moiety reduced). A type I interferon consisting of 165 amino acid residues with arginine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent.
Indications and Usage For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
Marketing Status Prescription
ATC Code L03AB05
DrugBank ID DB00105
KEGG ID D02745
MeSH ID D000077190
PubChem ID 71306834
TTD Drug ID D0P0WV
NDC Product Code 0085-4350; 0085-4352; 53713-0080; 0085-1133; 53713-0082; 53713-0079; 0085-4351; 53713-0078; 0085-1168; 53713-0081
Synonyms Interferon alpha-2 | Interferon alpha 2 | Interferon-alpha 2 | Interferon alpha-A | Interferon alpha A | LeIF A | IFN-alpha 2 | IFN-alpha-2 | Interferon alfa-2a | Interferon alfa 2a | Recombinant Interferon alpha-2a | Interferon alpha-2a, Recombinant | Recombinant Interferon alpha 2a | Roferon-A | Roferon A | RoferonA | Ro 22-8181 | Ro 22 8181 | Ro 228181 | Viferon | Sch-30500 | Sch 30500 | Sch30500 | Intron A (Interferon) | Reaferon | Interferon alfa-2b | Interferon alfa 2b | Interferon alpha-2b, Recombinant | Interferon alpha 2b, Recombinant | Recombinant Interferon alpha-2b | Recombinant Interferon alpha 2b | IFNalpha-2b, Recombinant | IFNalpha 2b, Recombinant | Recombinant IFNalpha-2b
Chemical Information
Molecular Formula C16H17Cl3I2N3NaO5S
CAS Registry Number 98530-12-2
SMILES CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypothyroidism14.11.01.012; 05.02.03.001--
Hypoventilation22.02.01.007--Not Available
Hypoxia22.02.02.003--
IIIrd nerve paralysis17.04.02.003; 06.05.02.011--Not Available
Ileus07.13.01.001--
Immune system disorder10.02.01.001--Not Available
Incontinence20.02.02.004; 17.05.01.006; 07.01.06.011--Not Available
Increased appetite14.03.01.003; 08.01.09.027--Not Available
Infection11.01.08.002--Not Available
Infection parasitic11.01.08.003--Not Available
Influenza22.07.02.001; 11.05.03.001--Not Available
Influenza like illness08.01.03.010--
Injection site erythema23.03.06.015; 12.07.03.001; 08.02.03.001--Not Available
Injection site haemorrhage12.07.03.005; 08.02.03.005; 24.07.01.010--Not Available
Injection site inflammation12.07.03.009; 08.02.03.008--Not Available
Injection site necrosis12.07.03.020; 08.02.03.020--Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Insomnia19.02.01.002; 17.15.03.002--
Irritability19.04.02.013; 08.01.03.011--
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Laceration23.03.11.004; 12.01.06.006--Not Available
Lacrimation increased06.08.02.004--
Laryngitis22.07.03.001; 11.01.13.001--
Leukopenia01.02.02.001--Not Available
Leukoplakia oral07.05.01.009--Not Available
Libido decreased19.08.03.001; 21.03.02.005--
Lipoma16.18.01.001; 15.09.01.001--Not Available
Liver function test abnormal13.03.01.013--Not Available
The 8th Page    First    Pre   8 9 10 11 12    Next   Last    Total 17 Pages